Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Increased buying in ONC by Institutions

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Feb 15, 2022 8:31pm

167 Views

Post# 34432180

RE:Increased buying in ONC by Institutions

Askretka's post on institutional ownership is excellent news!

It shows the burned, negative and nervous (per Yahoo Finance) that smart money investors see value here.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"